Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the hypertension treatment Benicar® (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age. Benicar was originally approved in 2002 for the treatment of hypertension in adults.

11 Feb 2010

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

QIAGEN N.V. and Celera Corporation today announced an agreement under which QIAGEN will distribute a Celera molecular multiplex assay. The assay is the next generation version of QIAGEN’s ResPlex II assay for detection of respiratory pathogens.

From QIAGEN Manchester Limited 11 Feb 2010

Women's heart-health awareness: Educational campaigns with evidence-based prevention messages needed

Racial gaps exist in women's heart-health awareness, women's knowledge of heart attack warning signs requires attention and nearly half of women report they would not call 9-1-1 if they were having heart attack symptoms, according to new research published in Circulation: Cardiovascular Quality and Outcomes, a journal of the American Heart Association.

11 Feb 2010

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates that the bioactive lipid lysophosphatidic acid (LPA), through its high affinity LPA1 receptor, is an important mediator of fibrogenesis in the bleomycin mouse model of scleroderma. Data will be presented as part of a poster session for the 1st Systemic Sclerosis World Congress to be held in Florence, Italy, February 11 to 13, 2010.

11 Feb 2010

Cardiology 2010 conference focuses on current treatments for children with heart disease

An international group of over 900 medical experts gathers today to discuss the most current treatments for children with heart disease. Affecting about 8 in every 1,000 children, congenital (present at birth) heart disease is the most common birth defect. In its severe forms, it is also the leading cause of death from birth defects in infants.

10 Feb 2010

Study shows more women die of heart disease each year than men

Cardiovascular disease (commonly referred to as heart disease) is the leading cause of death for women worldwide. Almost every minute, a woman in the U.S. dies from heart disease. Despite the prevalence of heart disease in women, a 2005 American Heart Association study showed that 92% of primary care physicians and 83% of cardiologists were not aware of the fact that more women than men die of heart disease each year.

10 Feb 2010

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.

10 Feb 2010

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration (FDA) regarding the potential risks associated with concomitant use of clopidogrel and PPIs.

10 Feb 2010

Rating of risk factors associated with cardiovascular disease: Low IQ follows cigarette smoking

While lower intelligence scores - as reflected by low results on written or oral tests of IQ - have been associated with a raised risk of cardiovascular disease, no study has so far compared the relative strength of this association with other established risk factors such as obesity, smoking and high blood pressure. Now, a large study funded by Britain's Medical Research Council, which set out to gauge the relative importance of IQ alongside other risk factors, has found that lower intelligence scores were associated with higher rates of cardiovascular disease and total mortality at a greater level of magnitude than found with any other risk factor except smoking.

10 Feb 2010

Racial gaps persist in women's heart-health awareness

10 Feb 2010

Low potassium levels increase risk of death in patients with heart failure and CKD

New research from the University of Alabama at Birmingham (UAB) says low potassium levels produce an increased risk of death or hospitalization in patients with heart failure and chronic kidney disease (CKD).

10 Feb 2010

Cholesterol lowering drugs also reduce risk of developing cataracts

Statins, a class of drugs used to lower cholesterol levels, have been successfully fighting heart disease for years. A new study from Tel Aviv University has now found that the same drugs cut the risks of cataracts in men by almost 40%.

10 Feb 2010

Early life stress could be a risk factor for cardiovascular disease in adulthood

"We think early life stress increases sensitivity to a hormone known to increase your blood pressure and increases your cardiovascular risk in adult life," said Dr. Jennifer Pollock, biochemist in the Vascular Biology Center at the Medical College of Georgia and corresponding author on the study published online in Hypertension.

10 Feb 2010

Insurer to take new role in assessing cancer treatments

UnitedHealthcare, one of the nation's biggest insurance companies, has decided to take a more active role in the care of its policy holders who are being treated for several types of cancer, The Wall Street Journal reports.

9 Feb 2010

Egg consumption does not raise blood cholesterol

February is American Heart Month, which means it's time to raise awareness about cardiovascular disease, the leading cause of death in America.

9 Feb 2010

Fourth-quarter and full-year 2009 results announced by Compugen

Compugen Ltd. today reported financial results for the fourth quarter and year ending December 31, 2009.

9 Feb 2010

Low potassium levels increase risk of death in patients with heart failure and CKD

9 Feb 2010

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, and Tulane University, today announced a major extension of the collaborative effort to combat viral hemorrhagic fever (VHF), an effort that will generate an additional $800,000 in contract revenue for Corgenix over the life of the contract.

9 Feb 2010

Resverlogix completes Phase 2 ASSERT trial enrollment 5 months ahead of schedule

Resverlogix Corp. announced today the completion of patient enrollment in the Phase 2 clinical study of its lead drug RVX-208. "The completion of enrollment for our Phase 2 ASSERT trial, a full 5 months ahead of our original schedule, is a very exciting achievement for our staff and our collaborators at the Cleveland Clinic.

9 Feb 2010

Health hazards: Clinging tobacco smoke reacts with nitrous acid and produces dangerous carcinogens

Nicotine in third-hand smoke, the residue from tobacco smoke that clings to virtually all surfaces long after a cigarette has been extinguished, reacts with the common indoor air pollutant nitrous acid to produce dangerous carcinogens. This new potential health hazard was revealed in a multi-institutional study led by researchers with the Lawrence Berkeley National Laboratory (Berkeley Lab).

9 Feb 2010

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

Women's heart-health awareness: Educational campaigns with evidence-based prevention messages needed

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

Cardiology 2010 conference focuses on current treatments for children with heart disease

Study shows more women die of heart disease each year than men

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Rating of risk factors associated with cardiovascular disease: Low IQ follows cigarette smoking

Racial gaps persist in women's heart-health awareness

Low potassium levels increase risk of death in patients with heart failure and CKD

Cholesterol lowering drugs also reduce risk of developing cataracts

Early life stress could be a risk factor for cardiovascular disease in adulthood

Insurer to take new role in assessing cancer treatments

Egg consumption does not raise blood cholesterol

Fourth-quarter and full-year 2009 results announced by Compugen

Low potassium levels increase risk of death in patients with heart failure and CKD

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Resverlogix completes Phase 2 ASSERT trial enrollment 5 months ahead of schedule

Health hazards: Clinging tobacco smoke reacts with nitrous acid and produces dangerous carcinogens

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Newsletters you may be interested in